In addition to monotherapy, some preclinical studies have shown that there is a synergistic blocking effect between the release of immunosuppressive tumor microenvironment and anti-PD-1/PD-L1 resulting from targeting of the ATP-adenosine pathway (including CD39 and CD73) (85). Here, ENTPD1 is linked to neoplasm.